INVA

Innoviva Inc

Apr 10 • 11:37AM ET

23.98

-0.22 -0.90 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD MRK ABBV AMGN REGN BIIB BMY VRTX PFE SAN

| Held by: IJR VTI IWM VB AVUV VBR VXF SPSM IWO DFAT

Index	RUT	P/E	7.85	EPS (ttm)	3.06	Insider Own	1.16%	Shs Outstand	74.64M	Perf Week	4.32%
Market Cap	1.78B	Forward P/E	10.85	EPS next Y	2.21	Insider Trans	0.00%	Shs Float	73.21M	Perf Month	6.97%
Enterprise Value	1.48B	PEG	-	EPS next Q	0.39	Inst Own	102.92%	Short Float	9.31%	Perf Quarter	22.05%
Income	271.17M	P/S	4.18	EPS this Y	-42.00%	Inst Trans	0.34%	Short Ratio	8.82	Perf Half Y	38.07%
Sales	425.13M	P/B	1.53	EPS next Y	15.46%	ROA	18.26%	Short Interest	6.82M	Perf YTD	19.97%
Book/sh	15.71	P/C	3.13	EPS next 5Y	-15.37%	ROE	29.09%	52W High	25.15 -4.62%	Perf Year	40.25%
Cash/sh	7.65	P/FCF	9.07	EPS past 3/5Y	- 10.35%	ROIC	18.81%	52W Low	16.52 45.17%	Perf 3Y	103.76%
Dividend Est.	-	EV/EBITDA	7.25	Sales past 3/5Y	325.77% 3.93%	Gross Margin	72.33%	Volatility	2.45% 2.30%	Perf 5Y	104.98%
Dividend TTM	-	EV/Sales	3.48	EPS Y/Y TTM	924.98%	Oper. Margin	38.52%	ATR (14)	0.57	Perf 10Y	81.96%
Dividend Ex-Date	Sep 08, 2015	Quick Ratio	13.85	Sales Y/Y TTM	14.12%	Profit Margin	63.78%	RSI (14)	66.61	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	14.64	EPS Q/Q	587.65%	SMA20	5.56%	Beta	0.43	Target Price	33.20
Payout	0.00%	Debt/Eq	0.23	Sales Q/Q	23.95%	SMA50	6.56%	Rel Volume	0.61	Prev Close	24.20
Employees	159	LT Debt/Eq	0.23	Earnings	Feb 25 AMC	SMA200	18.23%	Avg Volume	773.18K	Price	23.98
IPO	Oct 05, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	252.09% 11.68%	Trades		Volume	169,692	Change	-0.90%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-17-26	Initiated	BTIG Research	Buy	$35
Sep-30-25	Initiated	Goldman	Sell	$17
Aug-11-25	Initiated	Oppenheimer	Outperform	$45
Jul-14-25	Initiated	H.C. Wainwright	Buy	$40
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight	$26
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$55
Jun-18-24	Initiated	Cantor Fitzgerald	Overweight
Jul-20-22	Initiated	Goldman	Neutral	$16
Nov-20-17	Initiated	Deutsche Bank	Hold	$13

Mar-01-26 04:27AM	Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 - Here's Why (Insider Monkey)
Feb-28-26 08:26AM	Innoviva, Inc. (INVA): A Bull Case Theory (Insider Monkey)
06:45AM	Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer Conference (MarketBeat)
Feb-26-26 01:48PM	Celldex Therapeutics Stock Earns 88 RS Rating (Investor's Business Daily)
Feb-25-26 08:17PM	Nurix Therapeutics Stock Sees RS Rating Jump To 82 (Investor's Business Daily)
05:08PM	Loading…
05:08PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-24-26 01:14PM	CRISPR Therapeutics Stock Sees RS Rating Rise To 73 (Investor's Business Daily)
01:02PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Feb-19-26 08:21AM	AtaiBeckley names Michael Faerm as finance chief (Proactive)
08:00AM	Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Business Wire)
Feb-18-26 09:17AM	Bayer (BAYRY) Surges 6.0%: Is This an Indication of Further Gains? (Zacks)
Feb-04-26 07:55AM	Eli Lilly (LLY) Q4 Earnings and Revenues Beat Estimates (Zacks)
Jan-08-26 08:23AM	Biotech Is Heating Up-These 2 Red-Hot Stocks Stand Out (MarketBeat)
Dec-21-25 09:57AM	H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating (Insider Monkey)
04:56PM	Loading…
Dec-12-25 04:56PM	U.S. FDA Approves NUZOLVENCE (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents (Business Wire)
Dec-11-25 06:35PM	Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea (Business Wire)
Nov-25-25 07:00AM	Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-14-25 04:47AM	Beacon Biosignals secures $86m to advance AI-driven brain biomarker use (Medical Device Network)
Nov-05-25 06:40PM	Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates (Zacks) +12.89%
05:33PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Nov-04-25 08:00AM	Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-31-25 09:00AM	AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-30-25 07:55AM	Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-23-25 05:02AM	Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength? (Zacks)
Oct-21-25 08:00AM	Antheia Appoints Eric d'Esparbes as Chief Financial Officer (PR Newswire)
Oct-20-25 08:00AM	Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 (Business Wire)
Oct-14-25 07:30AM	Johnson & Johnson (JNJ) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-10-25 06:21AM	New Strong Buy Stocks for October 10th (Zacks)
09:40AM	Loading…
Oct-07-25 09:40AM	Are Investors Undervaluing Innoviva (INVA) Right Now? (Zacks)
08:00AM	Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025 (Business Wire)
Sep-17-25 02:27PM	Where is Innoviva (INVA) Headed According to Analysts? (Insider Monkey)
Aug-26-25 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-25 08:00AM	Innoviva Specialty Therapeutics Antimicrobial Therapies ZEVTERA and XACDURO Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award (Business Wire)
Aug-12-25 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update (PR Newswire)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly) +7.14%
Aug-06-25 05:06PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Jun-12-25 07:00AM	FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 (Business Wire)
Jun-10-25 06:00AM	Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults (Business Wire)
Jun-03-25 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
May-20-25 06:00AM	ZEVTERA (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections (Business Wire)
May-08-25 08:54AM	Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling (Insider Monkey)
May-07-25 05:52PM	Innoviva: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Apr-11-25 12:30AM	Harbor Health Care ETF Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 06:35PM	Victorias Secret, Bitdeer, and More Stocks See Activist Action (Barrons.com)
Mar-14-25 06:17PM	WEX, Lamb Weston, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-12-25 05:08PM	Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva (PR Newswire)
Mar-05-25 07:00AM	Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference (Business Wire)
Feb-26-25 04:35PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:04PM	Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-06-25 07:00AM	Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-17-24 07:25AM	Innoviva enters distribution, license agreement with Basilea for Zevtera (TipRanks)
Dec-16-24 07:00AM	Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera (ceftobiprole) (Business Wire)
01:15AM	Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera (ceftobiprole) in the United States (GlobeNewswire)
Nov-26-24 07:00AM	Innoviva to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-21-24 11:14PM	Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity (PR Newswire)
Nov-12-24 04:05PM	Innoviva to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-06-24 05:23PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Sep-04-24 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 10:54PM	INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:51PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Jul-09-24 01:30PM	The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 (InvestorPlace)
Jun-27-24 08:00AM	3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge (InvestorPlace)
Jun-18-24 09:51AM	Apple downgraded, Kroger upgraded: Wall Street's top analyst calls (The Fly)
Jun-03-24 07:00AM	Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-31-24 07:30AM	3 Under-$20 Stocks That Could Make You a Fortune (InvestorPlace)
May-20-24 04:06AM	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment (MT Newswires)
May-10-24 02:04PM	Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis (GuruFocus.com)
May-08-24 10:57PM	INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:09PM	Innoviva: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
07:00AM	Innoviva to Participate in the BofA Securities Health Care Conference (Business Wire)
Apr-24-24 07:00AM	Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 (Business Wire)
Mar-04-24 04:01PM	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva (PR Newswire)
Feb-29-24 04:56PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:37PM	Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-14-24 02:44AM	Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition (GuruFocus.com)
Jan-10-24 06:16PM	If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names (InvestorPlace)
Nov-18-23 07:03AM	Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc (GuruFocus.com)
Nov-03-23 06:00AM	Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million (GuruFocus.com)
Nov-01-23 05:32PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance) +6.92%
04:15PM	Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
04:05PM	Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea (Business Wire)
Sep-19-23 08:30AM	Innoviva to Participate in the Cantor Global Healthcare Conference (Business Wire)
Sep-18-23 08:00AM	XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults (Business Wire)
Aug-25-23 04:52PM	Innoviva Appoints Stephen Basso as Chief Financial Officer (Business Wire)
Aug-02-23 05:18PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-23-23 09:22AM	Investors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last year (Simply Wall St.)
Jul-11-23 08:53PM	Why These 7 Stocks Are the Best Ways to Play Biotech Right Now (InvestorPlace)
08:00AM	Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics (PR Newswire)
Jul-06-23 11:33AM	12 Best Extremely Profitable Stocks to Buy (Insider Monkey)
Jun-26-23 01:27AM	Insider trades & hedge fund hits: Elliott aims to oust NRG chief (Investing.com)
Jun-21-23 08:00PM	INVA: What does Argus have to say about INVA? (Argus Research)

Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INVA

Innoviva Inc

Upgrade your Finviz experience